Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
95% of athletes are diagnosed and treated for non-invasive heart disease, such as heart attacks or seizures, or implantable cardioverter defibrillator (ICD) shock.
Read Full NewsA nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.
The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.
Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.
REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis
1.
Words matter to people living with cancer. Here's how verbal microaggressions affect their mental state
2.
High Rate of Deep Remission for Relapsed/Refractory CLL Using Triple Regimen.
3.
Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients
4.
Sickle Cell Disease Drug Pulled From Global Markets
5.
Nasal therapeutic HPV vaccine could prevent cervical cancer
1.
Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer
2.
Understanding the Rare Disease: Werner Syndrome Explained
3.
Unveiling the Mystery Behind Castleman Disease – Understanding Its Causes and Symptoms
4.
Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know
5.
Understanding Lymphedema: Symptoms, Causes, and Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge